SC_02_015_FO_10-06-2021_Suppl_Figures.pdf (420.99 kB)
Download file

fon-2021-1277 suppl figures

Download (420.99 kB)
figure
posted on 29.11.2021, 15:13 authored by Mary A. Hall, Sherrif F. Ibrahim, Julia M. Kasprzak, Alison L. Fitzgerald, Jennifer Cox-SiegelJennifer Cox-Siegel, Sarah J. Kurley, Matthew S. Goldberg, Shannon C. Trotter, Ally-Khan Somani, Ashley Wysong, Sarah T. Arron
). *Archival sample collection ongoing. **Comprised of 307 previously-assessed (but not under clinical SOP, Wysong et al., JAAD 2021)21and 113 novel samples. CRF: case report form; SOP: standard operating procedure; QC: quality control; 40-GEP: 40-gene expression profile; cSCC:cutaneous squamous cell carcinoma.

Supplemental Figure 2. Further stratification of metastatic risk by the 40-GEP test per BWH or AJCC8 T stage for the cSCCValidation Cohort (n=420). 40-GEP, 40-gene expression profile; BWH, Brigham and Women’s Hospital; AJCC8, American Joint Committee on Cancer, Cancer Staging Manual, Eighth Edition; cSCC, cutaneous squamous cell carcinoma.

Enhanced Metastatic Risk Assessment in Cutaneous Squamous Cell Carcinoma with the 40-Gene Expression Profile Test

Funding

Castle Biosciences, Inc.

History